Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis – a five-year update

Abstract

Introduction: Following its marketing authorization for the treatment of ankylosing spondylitis (AS) in 2006 in the United States und in the European Union, adalimumab became one of the most frequently prescribed tumor necrosis factor (TNF) α blockers available for this indication. Recently, the label for adalimumab was extended to nonradiographic axial spondyloarthritis (nr-axSpA), which might be considered as an early stage of AS. The increasing number of patients with AS being treated with adalimumab raises issues concerning long-term safety, efficacy in the prevention of structural damage in the spine and high treatment costs.

Areas covered: Herein, we summarize data on efficacy and safety of adalimumab treatment in AS and nr-axSpA obtained over the past 5 years.

Expert opinion: Adalimumab is clinically effective and reasonably safe in the short-term and long-term treatment of patients with AS who do not respond to standard therapy. Recent data indicate good efficacy of adalimumab also in patients with nr-axSpA but only in the presence of objective signs of active inflammation. Yet unresolved questions relate to the ability of adalimumab to stop or retard structural damage development in the spine in patients with AS and nr-axSpA. The introduction of biosimilar drugs in the near future may potentially reduce the currently very high treatment costs associated with adalimumab treatment.

Keywords::

• adalimumab
• ankylosing spondylitis
• nonradiographic axial spondyloarthritis
• tumor necrosis factor α

Acknowledgments

During the review process, the manufacturer of the agent was offered an opportunity to comment. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. The authors had final responsibility to approve and submit the manuscript.